Smith MR: Non-Hodgkin's Lymphoma. Curr Probl Cancer. 1996, 20: 6-77.
Article
CAS
PubMed
Google Scholar
Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon AC, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D: Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. British Journal of Haematology. 2003, 120: 970-977. 10.1046/j.1365-2141.2003.04226.x.
Article
CAS
PubMed
Google Scholar
Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R: Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004, 101: 1835-1842. 10.1002/cncr.20587.
Article
CAS
PubMed
Google Scholar
Dumontet C, Morschhauser F, Solal-Celingy P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B: Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. British Journal of Haematology. 2001, 113: 772-778. 10.1046/j.1365-2141.2001.02795.x.
Article
CAS
PubMed
Google Scholar
Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P: Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma. 2004, 5: 45-49.
Article
CAS
PubMed
Google Scholar
Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, Bonodonna G, Seeber S, Nowrousian MR: Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 1999, 17: 3786-3792.
CAS
PubMed
Google Scholar
Nabhan C, Krett N, Gandhi V, Rosen S: Gemcitabine in hematologic malignancies. Curr Opin Oncol. 2001, 13: 514-521. 10.1097/00001622-200111000-00015.
Article
CAS
PubMed
Google Scholar
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology. 1998, 16: 2825-2833.
CAS
PubMed
Google Scholar
Alas S, Ng CP, Bonavida B: Rituximab Modifies the Cisplatin-mitochondrial Signaling Pathway, Resulting in Apoptosis in Cisplatin-resistant Non-Hodgkin's Lymphoma. Clinical Cancer Research. 2002, 8: 836-845.
CAS
PubMed
Google Scholar
Emmanouilides C, Jazirehi AR, Bonavida B: Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm. 2002, 17: 621-630. 10.1089/108497802320970226.
Article
CAS
PubMed
Google Scholar
Smith MR, Fang J, Joshi I: Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Molecular Cancer Therapeutics. 2004, 3: 1693-1699.
CAS
PubMed
Google Scholar
Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B: Chimeric anti-CD20 (IDEC_C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997, 12: 177-186.
Article
CAS
PubMed
Google Scholar
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallay R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N England J Med. 2002, 346: 235-242. 10.1056/NEJMoa011795.
Article
CAS
Google Scholar
Byrd JC, Rai KR, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005, 105: 49-53. 10.1182/blood-2004-03-0796.
Article
CAS
PubMed
Google Scholar
Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003, 22: 7359-7368. 10.1038/sj.onc.1206939.
Article
CAS
PubMed
Google Scholar
Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005, 24: 2121-2143. 10.1038/sj.onc.1208349.
Article
CAS
PubMed
Google Scholar
Smith MR, Xie T, Zhao-Zong Z, Joshi I: Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model. Clinical Cancer Research. 2001, 7: 400-406.
CAS
PubMed
Google Scholar
Kluin-Neilemans HC, Limpens J, Meerabux J, Beverstock GC, Jansen JH, de Jong D, Kluin PM: A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18) (q32;q21). Leukemia. 1991, 85: 221-224.
Google Scholar
Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A: A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet. 1993, 70: 62-67. 10.1016/0165-4608(93)90132-6.
Article
CAS
PubMed
Google Scholar
Freid J, Perez AG, Clarkson BD: Rapid hypotonic method for flow cytofluorometry of monolayer cell cultures. Some pitfalls in staining and data analysis. Journal of Histochemical Cytochemistry. 1978, 26: 921-933.
Article
Google Scholar
Brugge JS, Erikson RL: Identification of a transformation-specific antigen induced by an avian sarcoma virus. Nature. 1977, 269: 346-348. 10.1038/269346a0.
Article
CAS
PubMed
Google Scholar
Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55. 10.1016/0065-2571(84)90007-4.
Article
CAS
PubMed
Google Scholar
Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E: Anti-CD20 antibody (IDEC-C2B8, ribuximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica. 2002, 87: 33-43.
CAS
PubMed
Google Scholar
Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W: S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Research. 2001, 61: 1065-1072.
CAS
PubMed
Google Scholar
Bartek J, Lukas C, Lukas J: Checking on DNA damage in S phase. Nat Rev Mol Cell Biol. 2004, 5: 792-804. 10.1038/nrm1493.
Article
CAS
PubMed
Google Scholar
Nowak AK, Robinson BW, Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Research. 2002, 62: 2353-2358.
CAS
PubMed
Google Scholar
Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS: Neutrophils contribute to the biologican antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research. 2003, 9: 5866-5873.
CAS
PubMed
Google Scholar